Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
News|Articles|February 27, 2025
Interview Intersection: Expert Interviews From February 2025
Author(s)Emma Andrus, Editor
Dermatology Times is recapping our top expert interviews from the month of February.
Advertisement
Advertisement
Omar Noor, MD, FAAD, discussed the buy-and-bill process for biologic treatments in dermatology, emphasizing its efficiency and financial predictability. He outlined a streamlined workflow, from treatment selection and insurance coordination to rapid medication delivery and reimbursement. Despite its success in other medical fields, buy-and-bill remains underutilized in dermatology. Noor highlighted its benefits for patient care and practice management, particularly for biologics like tildrakizumab, and encouraged clinicians to adopt and customize the model.
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
A melanoma expert discusses gaps in dermoscopy education, cognitive bias during skin examinations, and strategies to improve early melanoma detection.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
Advertisement
Advertisement